Patrizia Russo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8016784/publications.pdf

Version: 2024-02-01

113 papers	2,922 citations	172457 29 h-index	197818 49 g-index
116 all docs	116 docs citations	116 times ranked	4077 citing authors

#	Article	IF	Citations
1	Psycho-cognitive assessment and quality of life in older adults with chronic obstructive pulmonary disease-carrying the rs4713916 gene polymorphism (G/A) of gene FKBP5 and response to pulmonary rehabilitation: a proof of concept study. Psychiatric Genetics, 2022, 32, 116-124.	1.1	4
2	DNA damage in dementia: Evidence from patients affected by severe Chronic Obstructive Pulmonary Disease (COPD) and meta-analysis of most recent literature. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2022, 878, 503499.	1.7	3
3	Nicotine upregulates ACE2 expression and increases competence for SARS-CoV-2 in human pneumocytes. ERJ Open Research, 2021, 7, 00713-2020.	2.6	25
4	Mild Cognitive Impairment and Mild Dementia: The Role of Ginkgo biloba (EGb 761Â®). Pharmaceuticals, 2021, 14, 305.	3.8	23
5	Daily Vegetables Intake and Response to COPD Rehabilitation. The Role of Oxidative Stress, Inflammation and DNA Damage. Nutrients, 2021, 13, 2787.	4.1	5
6	DNA damage in circulating leukocytes measured with the comet assay may predict the risk of death. Scientific Reports, 2021, 11, 16793.	3.3	36
7	Nicotine Changes Airway Epithelial Phenotype and May Increase the SARS-COV-2 Infection Severity. Molecules, 2021, 26, 101.	3.8	12
8	COVID-19 and smoking: is nicotine the hidden link?. European Respiratory Journal, 2020, 55, 2001116.	6.7	142
9	Microbiome in Chronic Obstructive Pulmonary Disease: Role of Natural Products Against Microbial Pathogens. Current Medicinal Chemistry, 2020, 27, 2931-2948.	2.4	3
10	Covid-19 and the role of smoking: the protocol of the multicentric prospective study COSMO-IT (COvid19 and SMOking in ITaly). Acta Biomedica, 2020, 91, e2020062.	0.3	3
11	Biomarkers of DNA damage in COPD patients undergoing pulmonary rehabilitation: Integrating clinical parameters with genomic profiling. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2019, 843, 111-117.	1.7	8
12	FKBP5 rs4713916: A Potential Genetic Predictor of Interindividual Different Response to Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease in a Real-Life Setting. International Journal of Molecular Sciences, 2019, 20, 2024.	4.1	21
13	Tobacco Smoking: Risk to Develop Addiction, Chronic Obstructive Pulmonary Disease, and Lung Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2019, 14, 39-52.	1.6	28
14	Flavonoids and Reduction of Cardiovascular Disease (CVD) in Chronic Obstructive Pulmonary Disease (COPD). Current Medicinal Chemistry, 2019, 26, 7048-7058.	2.4	7
15	Pharmacological Management of Chronic Obstructive Lung Disease (COPD). Focus on Mutations - Part 1. Current Medicinal Chemistry, 2019, 26, 1721-1733.	2.4	2
16	Pharmacological Management of Chronic Obstructive Lung Disease (COPD). Evidence from a Real-World Perspective - Part 2. Current Medicinal Chemistry, 2019, 26, 1734-1745.	2.4	2
17	Cognitive Impairment in Chronic Obstructive Pulmonary Disease (COPD): Possible Utility of Marine Bioactive Compounds. Marine Drugs, 2018, 16, 313.	4.6	2
18	Shorter telomere length in schizophrenia: Evidence from a real-world population and meta-analysis of most recent literature. Schizophrenia Research, 2018, 202, 37-45.	2.0	40

#	Article	IF	Citations
19	Clinical and genomic safety of treatment with Ginkgo biloba L. leaf extract (IDN) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 747 Td Complementary and Alternative Medicine, 2018, 18, 22.	3.7	21
20	Metabolic Disorder in Chronic Obstructive Pulmonary Disease (COPD) Patients: Towards a Personalized Approach Using Marine Drug Derivatives. Marine Drugs, 2017, 15, 81.	4.6	14
21	Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitors (AChEI) in Patients with Alzheimerâ€™s Disease. Current Drug Targets, 2017, 18, 1179-1190.	2.1	21
22	Action plans and coping strategies in elderly COPD patients influence the result of pulmonary rehabilitation: an observational study. European Journal of Physical and Rehabilitation Medicine, 2017, , .	2.2	6
23	New Drugs from Marine Organisms in Alzheimerâ€™s Disease. Marine Drugs, 2016, 14, 5.	4.6	52
24	DNA damage in non-communicable diseases: A clinical and epidemiological perspective. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 776, 118-127.	1.0	50
25	Deep sea as a source of novel-anticancer drugs: update on discovery and preclinical/clinical evaluation in a systems medicine perspective. EXCLI Journal, 2015, 14, 228-36.	0.7	21
26	Novel Therapeutic Strategy in the Management of COPD: A Systems Medicine Approach. Current Medicinal Chemistry, 2015, 22, 3655-3675.	2.4	15
27	Editorial (Thematic Issue: Disease Control and Active and Healthy Ageing: New Paradigms of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf	1.9	5
28	A Systems Medicine Clinical Platform for Understanding and Managing Non- Communicable Diseases. Current Pharmaceutical Design, 2014, 20, 5945-5956.	1.9	32
29	P4 Medicine Needs P4 Education. Current Pharmaceutical Design, 2014, 20, 6071-6072.	1.9	37
30	Alpha9Alpha10 Nicotinic Acetylcholine Receptors as Target for the Treatment of Chronic Pain. Current Pharmaceutical Design, 2014, 20, 6042-6047.	1.9	26
31	Beyond Acetylcholinesterase Inhibitors for Treating Alzheimer&aposs Disease: .α7-nAChR Agonists in Human Clinical Trials. Current Pharmaceutical Design, 2014, 20, 6014-6021.	1.9	22
32	EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation. International Journal of Medical Sciences, 2013, 10, 320-330.	2.5	106
33	Anticancer Drug Discovery from the Marine Environment. Recent Patents on Anti-Cancer Drug Discovery, 2012, 7, 218-232.	1.6	43
34	New Anticancer Drugs from Marine Cyanobacteria. Current Drug Targets, 2012, 13, 1048-1053.	2.1	23
35	Nicotinic receptor and tobacco-related cancer. Life Sciences, 2012, 91, 1087-1092.	4.3	46
36	Nicotine: specific role in angiogenesis, proliferation and apoptosis. Critical Reviews in Toxicology, 2012, 42, 68-89.	3.9	105

#	Article	IF	Citations
37	Î±7-Nicotinic Acetylcholine Receptors: An Old Actor for New Different Roles. Current Drug Targets, 2012, 13, 574-578.	2.1	28
38	Editorial [Hot Topic: Î±7-Nicotinic Receptor (Î±7-nAChR): One Target Different Diseases (Guest Editors:) Tj ETQq0 0 0 rgBT /Overlock 10	2.1	0
39	?7 nAChR in Airway Respiratory Epithelial Cells. Current Drug Targets, 2012, 13, 666-670.	2.1	12
40	Is ?7-nAChR a Possible Target for Lung Cancer and Malignant Pleural Mesothelioma Treatment?. Current Drug Targets, 2012, 13, 688-694.	2.1	22
41	A New â€œEraâ€•for the ?7-nAChR. Current Drug Targets, 2012, 13, 721-725.	2.1	8
42	The Sea Urchin, Paracentrotus lividus, as a Model to Investigate the Onset of Molecules Immunologically Related to the Î±-7 Subunit of Nicotinic Receptors During Embryonic and Larval Development. Current Drug Targets, 2012, 13, 587-593.	2.1	8
43	Concluding Notes of Special Issue â€œ?-7 Nicotinic Receptor (?7-nAChR): One Target Different Diseasesâ€• Current Drug Targets, 2012, 13, 726-727.	2.1	1
44	Inhibition of MDR1 activity and induction of apoptosis by analogues of nifedipine and diltiazem: an in vitro analysis. Investigational New Drugs, 2011, 29, 98-109.	2.6	35
45	Tobacco Habit: Historical, Cultural, Neurobiological, and Genetic Features of People's Relationship with an Addictive Drug. Perspectives in Biology and Medicine, 2011, 54, 557-577.	0.5	64
46	Adding Ipsilateral V20 and V30 to Conventional Dosimetric Constraints Predicts Radiation Pneumonitis in Stage IIIAâ€“B NSCLC Treated With Combined-Modality Therapy. International Journal of Radiation Oncology Biology Physics, 2010, 76, 110-115.	0.8	74
47	Î±7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and Mesothelioma?. Drug Discovery Today, 2009, 14, 822-836.	6.4	46
48	Inhibition of Nonneuronal Î±7-Nicotinic Receptor for Lung Cancer Treatment. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 1141-1150.	5.6	47
49	Use of Pharmacotherapy for Smoking Cessation in Italy. Archives of Internal Medicine, 2009, 169, 1927.	3.8	8
50	Use of the Semiconductor Nanotechnologies “Quantum Dots” for in vivo Cancer Imaging. Recent Patents on Anti-Cancer Drug Discovery, 2009, 4, 207-215.	1.6	6
51	Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance. Current Medicinal Chemistry, 2009, 16, 1688-1703.	2.4	124
52	Natural agents targeting the Î±7â€•nicotinicâ€•receptor in NSCLC: A promising prospective in antiâ€•cancer drug development. International Journal of Cancer, 2008, 122, 1911-1915.	5.1	73
53	Computed tomography screening for lung cancer. Cancer, 2008, 112, 2520-2521.	4.1	2
54	Novel Prognostic Groups in Thymic Epithelial Tumors: Assessment of Risk and Therapeutic Strategy Selection. International Journal of Radiation Oncology Biology Physics, 2008, 71, 420-427.	0.8	21

#	Article	IF	Citations
55	Factors predicting poor survival after resection of stage IA nonâ€“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2008, 136, 241-242.	0.8	4
56	The cholinergic system and cancer. Seminars in Cancer Biology, 2008, 18, 211-217.	9.6	69
57	Targeting Î±7-nicotinic receptor for the treatment of pleural mesothelioma. European Journal of Cancer, 2008, 44, 2296-2311.	2.8	29
58	Smoking Out the Cholinergic Component in Lung Cancer. Clinical Cancer Research, 2008, 14, 6742-6743.	7.0	3
59	Computed Tomography Screening for Lung Cancer in a High-Risk Population: Update on Current Status. Journal of the National Cancer Institute, 2008, 100, 1043-1044.	6.3	4
60	In vivo Cancer Imaging with Semiconductor Quantum Dots. Current Pharmaceutical Analysis, 2008, 4, 197-205.	0.6	11
61	K-ras Mutations in Circulating DNA From Pancreatic and Lung Cancers. Pancreas, 2008, 37, 101-102.	1.1	14
62	Nicotine, Lung and Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2007, 7, 461-466.	1.7	54
63	Commentary: Early Diagnosis of Lung Cancer: Where Do We Stand?. Oncologist, 2007, 12, 1433-1436.	3.7	4
64	Inflammation and thoracic surgery: a complex interaction. European Journal of Cardio-thoracic Surgery, 2007, 32, 950-950.	1.4	1
65	Role of Tyrosine Kinase Inhibitor Molecules in Non Small Cell Lung Cancer:From Benchside to Bedside. Current Respiratory Medicine Reviews, 2007, 3, 159-167.	0.2	0
66	Post-operative respiratory rehabilitation after lung resection for non-small cell lung cancer. Lung Cancer, 2007, 57, 175-180.	2.0	154
67	Pre-operative pulmonary rehabilitation and surgery for lung cancer. Lung Cancer, 2007, 57, 118-119.	2.0	126
68	Prognostic role of K-Ras mutations in non-small cell lung cancer: Still an issue for open debate. Lung Cancer, 2006, 53, 393-395.	2.0	14
69	Multimodality treatment of unresectable stage III nonâ€“small cell lung cancer: Interim analysis of a phase II trial with preoperative gemcitabine and concurrent radiotherapy. Journal of Thoracic and Cardiovascular Surgery, 2006, 131, 314-321.e3.	0.8	16
70	Farnesyltransferase Inhibitors: Overview of their Action and Role in Solid Malignancy Therapy. Letters in Drug Design and Discovery, 2005, 2, 26-35.	0.7	9
71	Mutations in K-ras Codon 12 Detected in Plasma DNA Are Not an Indicator of Disease in Patients with Non-Small Cell Lung Cancer. Clinical Chemistry, 2005, 51, 1313-1314.	3.2	18
72	Farnesyltransferase Inhibitors and Human Malignant Pleural Mesothelioma: A First-Step Comparative Translational Study. Clinical Cancer Research, 2005, 11, 2026-2037.	7.0	7

#	Article	IF	Citations
73	Molecular Mechanisms of Hexavalent Chromiumâ€“Induced Apoptosis in Human Bronchoalveolar Cells. American Journal of Respiratory Cell and Molecular Biology, 2005, 33, 589-600.	2.9	58
74	Role of the Non-Neuronal Human Cholinergic System in Lung Cancer and Mesothelioma: Possibility of New Therapeutic Strategies. Anti-Cancer Agents in Medicinal Chemistry, 2004, 4, 535-542.	7.0	30
75	Non-Small Cell Lung Cancer: From Cytotoxic Systemic Chemotherapy to Molecularly Targeted Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2004, 4, 231-245.	7.0	3
76	Î±7-Nicotinic Acetylcholine Receptors Affect Growth Regulation of Human Mesothelioma Cells. Cancer Research, 2004, 64, 135-145.	0.9	110
77	Networking for excellence in lung cancer: paper vs. research work. Lung Cancer, 2004, 43, 363-365.	2.0	0
78	Malignant pleural mesothelioma: time for translational research. Lancet Oncology, The, 2004, 5, 591.	10.7	8
79	Farnesylated Proteins as Anticancer Drug Targets: From Laboratory to the Clinic. Anti-Cancer Agents in Medicinal Chemistry, 2004, 4, 123-138.	7.0	28
80	The role of the surgeon in translational research. Lancet, The, 2003, 362, 1082.	13.7	10
81	c-mycDown-Regulation Induces Apoptosis in Human Cancer Cell Lines Exposed to RPR-115135 (C31H29NO4), a Non-Peptidomimetic Farnesyltransferase Inhibitor. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 37-47.	2.5	23
82	Increasing Complexity of Farnesyltransferase Inhibitors Activity: Role in Chromosome Instability. Current Cancer Drug Targets, 2003, 3, 109-118.	1.6	10
83	Nonpeptidomimetic Farnesyltransferase Inhibitor RPR-115135 Increases Cytotoxicity of 5-Fluorouracil: Role of p53. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 220-226.	2.5	5
84	Human papillomavirus type 16 E6-enhanced susceptibility to apoptosis induced by TNF in A2780 human ovarian cancer cell line. International Journal of Cancer, 2002, 97, 732-739.	5.1	27
85	RPR-115135, a farnesyltransferase inhibitor, increases 5-FU- cytotoxicity in ten human colon cancer cell lines: Role of p53. International Journal of Cancer, 2002, 100, 266-275.	5.1	43
86	Induction of micronuclei by a new non-peptidic mimetic farnesyltransferase inhibitor RPR-115135: role of gene mutations. Mutagenesis, 2001, 16, 423-430.	2.6	5
87	RPR-115135, a new non peptidomimetic farnesyltransferase inhibitor, induces G0/G1 arrest only in serum starved cells. International Journal of Oncology, 2001, 18, 855-62.	3.3	2
88	Inactivation of p53 in a Human Ovarian Cancer Cell Line Increases the Sensitivity to Paclitaxel by Inducing G2/M Arrest and Apoptosis. Experimental Cell Research, 1998, 241, 96-101.	2.6	81
89	Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: Possible role of p53. , 1997, 72, 155-159.		21
90	Tumour necrosis factor enhances the therapeutic effect of mitoxantrone in human ovarian cancer xenograft. Cytokine, 1996, 8, 330-333.	3.2	2

#	Article	IF	Citations
91	Interactions between taxol and camptothecin. Anti-Cancer Drugs, 1996, 7, 531-534.	1.4	5
92	Interferon-Î± or Î² potentiate platinum analogous in human glioblastoma cell lines. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1995, 348, 131-135.	1.1	5
93	â€œAtypicalâ€•multidrug resistance in human ovarian cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3). Journal of Cancer Research and Clinical Oncology, 1995, 121, 155-163.	2.5	1
94	Induction of DNA double-strand breaks by 8-methoxycaffeine: cell cycle dependence and comparison with topoisomerase II inhibitors. Carcinogenesis, 1994, 15, 2491-2496.	2.8	5
95	Sister-chromatid exchanges, chromosomal aberrations and cytotoxicity produced by topoisomerase II-targeted drugs in sensitive (A2780) and resistant (A2780-DX3) human ovarian cancer cells: Correlations with the formation of DNA double-strand breaks. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1994, 311, 21-29.	1.0	27
96	Circumvention of Atypical Multidrug Resistance with Tumor Necrosis Factor. Japanese Journal of Cancer Research, 1994, 85, 135-138.	1.7	5
97	Potentiation of TNF-mediated cell killing by mitoxantrone. Biochemical Pharmacology, 1993, 46, 1199-1206.	4.4	9
98	Potentiation by Tumor Necrosis Factor of Mitoxantrone Cytotoxicity to Human Ovarian Cancer Cell Lines. Japanese Journal of Cancer Research, 1992, 83, 684-687.	1.7	5
99	Potentiation of Topoisomerase I and II Inhibitors Cell Killing by Tumor Necrosis Factor: Relationship to DNA Strand Breakage Formation. Japanese Journal of Cancer Research, 1992, 83, 1132-1136.	1.7	13
100	Effect of recombinant human tumor necrosis factor on A2774 human ovarian cancer cell line: Potentiation of mitoxantrone cytotoxicity. Gynecologic Oncology, 1991, 41, 52-55.	1.4	15
101	Human Granulocyte-Macrophage Colony-stimulating Factor Is a Growth Factor Active on Human Ovarian Cancer Cells. Japanese Journal of Cancer Research, 1991, 82, 1196-1198.	1.7	17
102	Generation and Characterization of a Low-Degree Drug-Resistant Human Tumor Cell Line. Oncology, 1990, 47, 488-494.	1.9	16
103	Studies on DNA binding of caffeine and derivatives: evidence of intercalation by DNA-unwinding experiments. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1989, 1007, 112-115.	2.4	39
104	DNA damage in mouse and rat liver by caprolactam and benzoin, evaluated with three different methods. Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental Or Occupational Exposure, 1989, 224, 379-384.	1.2	10
105	DNA Fragmentation or Changes in Chromatin Conformation. Results with Two Model Systems: Promotion in Rat Liver Carcinogenesis and Proliferation in Mastocytes. , 1988, , 195-202.		0
106	Assay of phenacetin genotoxicity using in vitro and in vivo test systems. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1985, 16, 355-377.	2.3	12
107	Effects of vitamin E on liver DNA. Cancer Letters, 1984, 25, 163-170.	7.2	8
108	Alkaline DNA fragmentation, DNA disentanglement evaluated viscosimetrically and sister chromatid exchanges, after treatment in vivo with nitrofurantoin. Chemico-Biological Interactions, 1983, 45, 77-94.	4.0	28

#	Article	IF	Citations
109	Detectabilityin vivo of stabilized intercalating agents with the alkaline elution technique comparison within vivo sister chromatid exchange induction. Journal of Applied Toxicology, 1983, 3, 58-62.	2.8	6
110	Quantitative predictivity of the transformationin vitroassay compared with the ames test. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1983, 12, 483-510.	2.3	17
111	DNA damage induced by auramine O in liver, kidney, and bone marrow of rats and mice, and in a human cell line (alkaline elution assay and SCE induction). Journal of Toxicology and Environmental Health - Part A: Current Issues, 1982, 9, 941-952.	2.3	21
112	DNA damage in liver of mice treated with N-nitrodimethylamine. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1982, 103, 207-211.	1.1	7
113	DNA damage in liver of rats treated with nitrofurantoin. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1982, 105, 377-382.	1.1	5